Advertisement IntegenX gets QTDP grants - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

IntegenX gets QTDP grants

IntegenX, a developer of automated DNA and RNA based sample preparation systems, has got four grants of $976,000 under the Qualifying Therapeutic Discovery Project Program (QTDP).

The IntegenX programs focus on developing platforms for DNA sample preparation, sequencing library preparation and sample-to-answer analysis of human genotypes.

IntegenX president and CEO Stevan Jovanovich said that they are pleased to receive federal recognition that their platforms have the potential for impacting the development of therapeutics, molecular diagnostics, and discovery of genetic markers that will improve outcomes for patients.

"These awards provide IntegenX with additional support to continue development of our products and to accelerate advancing them to the market," Jovanovich said.